A new combined treatment for post-concussion syndrome: a pilot trial

Not Applicable

• Conditions: Post-concussion syndrome; Mental and Behavioural Disorders; Postconcussional syndrome

• Registration Number: ISRCTN45733939
• Lead Sponsor: Durham University

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Start: 2022-03-30
• Last Update Posted: 11 September 2023
• Study Completion: 2025-06-01

Recruitment & Eligibility

• Status: Ongoing
• Sex: All
• Target Recruitment: 18

Inclusion Criteria

1. PCS patients, aged 18 to 64 years. PCS is defined as the persistence of concussion symptoms, for more than 3 months after the initial concussion event
2. Current PCS confirmed by the presence of more than three symptoms on the Rivermead PCS
3. Not using any other pharmaceutical treatment for the management of PCS, e.g. antidepressants
4. Can provide signed informed consent

Exclusion Criteria

1. Pregnancy
2. Breastfeeding
3. Hepatic insufficiency
4. Renal impairment
5. Any of the following BNF contraindications for cinnarizine: acute porphyrias; epilepsy; Parkinson's disease; prostatic hypertrophy; pyloroduodenal obstruction; susceptibility to angle-closure glaucoma; urinary retention
6. Any of the following BNF contraindications for piracetam: gastric ulcer; history of haemorrhagic stroke; increased risk of bleeding; recent or planned major surgery; underlying disorders of haemostasis; cerebral haemorrhage; Huntington's chorea

Study & Design

• Study Type: Interventional
• Study Design: Not specified